RxDoctor Payments Data

Svijetlana Begovic, MD

Internal Medicine · Bryan, TXNPI 1285627315

Payments from drug & device makers

$2,817in general payments, 2019–2025

Across 176 payments — averaging $16.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$864
  • Amgen$269
  • Sanofi-aventis U.S. LLC$192
  • Johnson & Johnson$178
  • AbbVie$159
  • Pfizer$124
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$2,807100%
  • Education$100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,817 in reported general payments places this provider in the 80th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$120,046
Medicare patients
257
Services billed
1,705

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide104$125,268
EliquisApixaban37$40,041
RybelsusSemaglutide22$31,580
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog16$27,088
FarxigaDapagliflozin Propanediol19$20,949
JardianceEmpagliflozin14$20,056
MounjaroTirzepatide20$19,989
Repatha SyringeEvolocumab25$15,679
VascepaIcosapent Ethyl17$9,946
PremarinEstrogens, Conjugated12$6,461
Lantus SolostarInsulin Glargine,hum.Rec.Anlog26$6,292
SynthroidLevothyroxine Sodium92$5,305
Levothyroxine Sodium361$5,070
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate14$4,660
Rosuvastatin Calcium292$4,138

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$864$156,848126 claims
PfizerEliquis, Premarin$124$46,50249 claims
AstraZenecaFarxiga$99$20,94919 claims
Boehringer IngelheimJardiance$75$20,05614 claims
Lilly USA, LLCMounjaro$120$19,98920 claims
AbbVieSynthroid, Armour Thyroid$159$6,389104 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Bryan

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →